MOUNTAIN VIEW, Calif., May 28 /PRNewswire/ -- Clontech Laboratories, Inc., a wholly-owned subsidiary of Takara Bio Inc., today announced the upcoming (June 1, 2009) release of the Xfect(TM) and Xfect(TM) Stem transfection reagents. These novel transfection reagents are based on biodegradable nanoparticles that permit superior transfection efficiency of plasmid DNA into mammalian cells. For added ease of use, transfections can be carried out entirely in the presence of serum. Xfect shows high efficiency over a broad range of cell types, while Xfect Stem meets the highly specialized requirements for mouse embryonic stem cell transfections.
Carol Lou, General Manager of Clontech Laboratories, Inc., comments: "Clontech has a long history of leadership in developing technologies for gene delivery and expression. We identified a need for cost-effective, efficient and non-toxic transfection reagents, and responded with an innovative solution. We are pleased to announce the addition of Xfect transfection reagents to our wide range of established products, including our Lenti-X(TM) and Adeno-X(TM) viral delivery systems and vectors for Tet-On(R) Advanced- and ProteoTuner(TM)-based inducible expression."
Researchers recognize that effective, nontoxic DNA transfer is a vital first step in basic and applied research, including studies of gene regulation, protein expression, and function; the development of transgenic organisms; and therapeutic gene delivery. Clontech has a patent license from M.I.T. based on research by scientists at M.I.T. who screened more than 2,300 candidate polymers to identify novel biodegradable nanoparticles that facilitate exceptional transfection efficiency. Under the license, Clontech optimized two of the lead compounds from the screen to create the Xfect and Xfect Stem reagents.
About Clontech Laboratories, Inc.
Clontech Laboratories, Inc., a wholly-owned subsidiary of Takara Bio Inc., develops, manufactures, and distributes a wide range of life science research reagents under the Clontech and Takara brands. Key products include high-performance qPCR and PCR reagents (including the Ex Taq(TM), LA Taq(TM), Titanium(TM), and Advantage(R) enzymes); RT enzymes and SMART(TM) library construction kits; the innovative In-Fusion(TM) cloning system; Tet-based inducible gene expression systems; and a range of Macherey-Nagel nucleic acid purification tools. These and other products support applications including gene discovery, regulation, and function; protein expression and purification; RNAi and stem cell studies; and plant and food research. For more information visit www.clontech.com.
About Takara Bio Inc.
Takara Bio Inc. is an innovative biotechnology company based in Shiga, Japan. As a world leader in biotechnology research and development, Takara Bio was the first company to market PCR technology in Japan and is also the developer of the RetroNectin(R) reagent, which is a world-standard in gene therapy protocols. In addition to providing research reagents and equipment to the life science research market, Takara Bio has active research and product development activities in the fields of gene and cell-based therapy, and agricultural biotechnology; and is committed to preventing disease and improving the quality of life for all people through the use of biotechnology. Through strategic alliances with other industry leaders, the Company aims to extend its reach around the world. More information is available at http://www.takara-bio.com.
SOURCE Clontech Laboratories, Inc.